Despite optimized triple therapy, many COPD patients continue to experience exacerbations, highlighting significant unmet needs—particularly in the eosinophilic subgroup. Blood eosinophil count (BEC) serves as a key biomarker to identify patients at higher risk and guide targeted treatment, yet remains under-recognized in clinical practice.

Interleukin-5 (IL-5) plays a central role not only in eosinophil regulation but also in airway remodeling, mucus hypersecretion, and epithelial dysfunction across the asthma–COPD continuum. These shared mechanisms support a shift toward phenotype-driven disease management.

Targeting IL-5 offers a mechanism-based approach to reduce exacerbations and potentially stabilize disease progression.

This session will integrate global evidence and local clinical insights to highlight the importance of early identification and precision treatment in eosinophilic COPD.